NCT01808339View on ClinicalTrials.gov

To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Asthma
Interventions
DRUG

Fluticasone Furoate (FF)

Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).

DRUG

Placebo

Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01808339 - To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma | Biotech Hunter | Biotech Hunter